TP53 and lung carcinoma: Furthermore, TP53 mutations have been associated with increased resistance to ferroptosis in lung cancer, and this resistance is attributed to the inhibition of forkhead box M1 relieved, which in turn activates myocyte-specific enhancer factor 2C providing stress protection against ferroptosis inducers (31).